Risk Factors for Dementia with Lewy Bodies (S24.005)

Abstract

Objective: To determine the risk factors associated with Dementia with Lewy Bodies (DLB) in a population-based case-control study. Background DLB is the second most common form of dementia and shares features with Alzheimer9s Disease (AD) and Parkinson9s disease with dementia (PDD). No prior studies have comprehensively assessed risk factors for DLB. Design/Methods: We identified 147 subjects with incident DLB and without a concomitant diagnosis of AD. Each DLB subject was matched for sex and age (+/- 5 years) with two cognitively-normal control (NC) subjects, and compared to 221 subjects with AD. We asked subjects and carers about known AD and PDD risk factors during enrollment and follow-up. We also reviewed their complete medical records to verify exposure information. Results: For DLB compared to NCs, the nominal odds ratio (OR) for a history of depression was 11.9 (p Conclusions: Like PD, DLB was associated with male preponderance, pre-existing anxiety and depression and early oophorectomy in females. Like AD it was associated with shorter life-span, stroke and the APOEe4 allele. It differed from AD in regard to gender and education. Supported by: Grants P50 AG16574 and P01 AG07216 from the National Institute on Aging, by the Robert H. and Clarice Smith and Abigail Van Buren Alzheimer9s Disease Research Program and R01 AG15866. Disclosure: Dr. Boot has nothing to disclose. Dr. Orr has nothing to disclose. Dr. Ferman has nothing to disclose. Dr. Roberts has received research support from Abbott Laboratories. Dr. Pankratz has received research support from Abbott Laboratories, Inc. Dr. Dickson has nothing to disclose. Dr. Ahlskog has nothing to disclose. Dr. Knopman has received personal compensation for activities with Lilly Pharmaceuticals as a data safety monitoring board member. Dr. Knopman has received personal compensation in an editorial capacity for Neurology. Dr. Knopman has received research support from Elan, Forest, and Baxter. Dr. Petersen has received personal compensation for activities with Pfizer, Inc., Janssen Alzheimer9s Immunotherapy, Elan Pharmaceuticals, and GE Healthcare. Dr. Boeve has nothing to disclose.